Measuring Blood Markers in People With Lupus Kidney Disease
Studies blood markers, including interleukin-17, in adults with lupus nephritis.
Plain-language title generated from the registry record
Registry title: Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
Key facts
- Where
- Sohag, EgyptSee the site
Where in Egypt
- Sohag University HospitalSohag, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sohag University
- Trial code
- NCT07017868
- Record updated
- 12 June 2025
- Original description
Systemic lupus erythematosus (SLE) is a chronic inflammatory multisystem autoimmune disease characterized by pathogenic autoantibodies production against nuclear structures . SLE affecting mainly women of childbearing age and is characterized by unpredictable flares and remissions. Disease severity varied from a mild episodic disorder to a rapidly progressive life-threatening illness. The kidney is the most commonly involved visceral organ in SLE. Therefore, identifying new noninvasive biomarkers of LN severity and outcome is mandatory. IL-17 is a potent pro-infammatory cytokine that amplifes T-cell activation and stimulates fibroblast cells, endothelial, and epithelial cells to produce several pro-infammatory mediators, including IL-1β, IL-6, and TNF-α. IL-17 receptor signaling enhances the expression of multiple pro-infammatory mediators. Hence, IL-17 enhances the production of neutrophil-attracting chemokinesRead full original descriptionShow less
Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
Systemic lupus erythematosus (SLE) is a chronic inflammatory multisystem autoimmune disease characterized by pathogenic autoantibodies production against nuclear structures . SLE affecting mainly women of childbearing age and is characterized by unpredictable flares and remissions. Disease severity varied from a mild episodic disorder to a rapidly progressive life-threatening illness. The kidney is the most commonly involved visceral organ in SLE. Therefore, identifying new noninvasive biomarkers of LN severity and outcome is mandatory. IL-17 is a potent pro-infammatory cytokine that amplifes T-cell activation and stimulates fibroblast cells, endothelial, and epithelial cells to produce several pro-infammatory mediators, including IL-1β, IL-6, and TNF-α. IL-17 receptor signaling enhances the expression of multiple pro-infammatory mediators. Hence, IL-17 enhances the production of neutrophil-attracting chemokines
Inclusion: ● Aged ≥18 years; SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls; Patients cooperative and can answer questions; Patients who are able and willing to give written informed consent.
Exclusion: ● Individuals with other autoimmune diseases; Patients receive any hyperuricemia treatment; Pregnancy; Malignancy; Diabetes; Hypertension; Heart failure; Hepatic diseases; Chronic renal failure other than lupus nephritis; Renal artery stenosis; Renal vein thrombosis; Intrarenal arteriovenous fistula; Obstructive nephropathy; Urinary tract obstruction that could affect RI of intra renal arteries; Uncooperative patients; Patients not able and willing to give written informed consent.